Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 2/2017

01-04-2017 | LETTER TO THE EDITOR

Melatonin as an Agent for Cardioprotection in Patients with ST-Elevation Myocardial Infarction and Short Ischaemic Time

Authors: Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez, Russel J. Reiter

Published in: Cardiovascular Drugs and Therapy | Issue 2/2017

Login to get access

Excerpt

To the Editor …
Literature
1.
Kloner RA, Hale SL, Dai W, Shi J. Cardioprotection: Where to from here? Cardiovasc Drugs Ther. 2017. (in press)
2.
Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Melatonin for cardioprotection in ST elevation myocadial infarction: are we reading for the challenge? Heart. 2017. (in press)
3.
Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014;29:325–33.
4.
Pandi-Perumal SR, BaHammam AS, Ojike NI, et al. Melatonin and human cardiovascular disease. J Cardiovasc Pharmacol Ther. 2017. (in press)
5.
Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. The role of melatonin in acute myocardial infarction. Front Biosci (Landmark Ed). 2012;17:2433–41.CrossRef
6.
Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253–78.CrossRefPubMed
7.
Opie LH, Lecour S. Melatonin has multiorgan effects. Eur Heart J Cardiovasc Pharmacother. 2016;2:258–65.CrossRefPubMed
8.
Simko F, Baka T, Paulis L, Reiter RJ. Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review. J Pineal Res. 2016;61:127–37.CrossRefPubMed
9.
Dominguez-Rodriguez A, Abreu-Gonzalez P, De la Torre-Hernandez JM, et al. Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: results of the Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial. J Pineal Res. 2017;62.
10.
Hausenloy DJ, Botker HE, Engstrom T, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J. 2017. (in press)
Metadata
Title
Melatonin as an Agent for Cardioprotection in Patients with ST-Elevation Myocardial Infarction and Short Ischaemic Time
Authors
Alberto Dominguez-Rodriguez
Pedro Abreu-Gonzalez
Russel J. Reiter
Publication date
01-04-2017
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 2/2017
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-016-6708-8

Other articles of this Issue 2/2017

Cardiovascular Drugs and Therapy 2/2017 Go to the issue

ORIGINAL ARTICLE

Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study

ORIGINAL ARTICLE

Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis

ORIGINAL ARTICLE

SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

ORIGINAL ARTICLE

Exploring the Role of TRPV and CGRP in Adenosine Preconditioning and Remote Hind Limb Preconditioning-Induced Cardioprotection in Rats

REVIEW ARTICLE

The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action

ORIGINAL ARTICLE

Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits